Objective. Enthesitis is an important pathophysiologic component of psoriatic arthritis (PsA). HLA genes are implicated in the pathogenesis of PsA. Little is known about the relationship between HLA genetic susceptibility markers and enthesitis in PsA patients. Our aim was to examine the association between HLA genetic susceptibility markers and sonographic enthesitis in PsA.
Methods. A cross-sectional analysis was conducted in patients with PsA. Sonographic enthesitis was assessed according to the Madrid Sonography Enthesitis Index scoring system. HLA genotyping was performed using sequence-specific oligonucleotide probes. The association between 6 HLA susceptibility markers of PsA and the severity of sonographic enthesitis was assessed using multivariate regression models adjusted for age, sex, body mass index, and disease duration.
Results. Two hundred twenty-five patients were included, 57.8% of whom were men. The mean AE SD age was 56.1 AE 12.7 years, and the mean AE SD PsA duration was 16.9 AE 12.3 years. In the multivariate regression model, HLA-B*27 was associated with a higher enthesitis score (b = 4.24 [95% confidence interval {95% CI} 0.02, 8 .46]), and the interaction between HLA-B*27 and PsA duration was statistically significant, showing an increasing effect of HLA-B*27 with longer PsA duration (b = 4.62 [95% CI 1.38, 7 .86]).
Conclusion. HLA-B*27 is associated with more severe sonographic enthesitis in PsA, particularly in patients with longer disease duration. This finding highlights the possible role of genetic variants in predisposing to PsA subphenotypes.
Psoriasis is an inflammatory skin disease affecting 2-3% of the general population (1) . Up to one-third of these patients develop an inflammatory arthritis termed psoriatic arthritis (PsA) (2) . PsA is a heterogeneous disease manifesting with various features of articular and extraarticular inflammation. Enthesitis is a common periarticular musculoskeletal feature of PsA, affecting approximately one-third of the patients (3, 4) . According to some studies, enthesitis is a key pathophysiologic feature in spondyloarthritis (SpA) (5-7). McGonagle et al proposed the synovio-entheseal complex model, suggesting that the enthesis is the initial site of inflammation spreading to other adjacent periarticular and articular sites, which may explain other features of PsA, such as synovitis and spondylitis (8) .
Most of the entheseal sites are located in the subcutaneous tissue, without clear margins or prominences, which makes the clinical assessment of enthesitis quite challenging (9) . An alternative diagnostic option for enthesitis is musculoskeletal ultrasound (MSUS), which is an available and affordable modality that can be used to assess different entheseal sites in a short time period (10) . Several studies that compared clinical and sonographic assessment of enthesitis showed that the latter has better sensitivity and specificity (11, 12) . MSUS is therefore emerging as the preferred method to assess enthesitis.
The pathogenesis of PsA is related to both environmental and genetic risk factors. Biomechanical stress, physical trauma, obesity, and infection have been identified as potential nongenetic risk factors for PsA (13) (14) (15) (16) . Within this group, the HLA-B alleles HLA-B*27, B*08:01, B*38:01, and B*39:01 have been associated with PsA, while HLA-C*06:02 has been associated with psoriasis (17, 18) .
HLA alleles have also been associated with subphenotypes of PsA, particularly HLA-B*27, which was linked with the development of more severe disease phenotypes including radiographic joint damage and axial involvement (19, 20) . However, there is limited information regarding the association between HLA risk alleles for PsA and enthesitis. Investigating this link could elucidate the role of genetic factors in the development of the various subphenotypes of PsA. The aim of this study was to examine the association between HLA genetic susceptibility markers and sonographic enthesitis in patients with PsA.
PATIENTS AND METHODS
Setting and study population. A cross-sectional study was conducted in patients enrolled in the University of Toronto PsA cohort. Patients in this cohort are followed up prospectively according to a standard protocol at 6-12-month intervals. At each visit, all patients are assessed with a complete history and physical examination including recording of demographic information, medications, body mass index (BMI), counts of tender, swollen, and clinically damaged joints, dactylitis, clinical enthesitis assessed according to the Spondyloarthritis Research Consortium of Canada enthesitis index (21) , Psoriasis Area and Severity Index (PASI) (22) , and the presence of psoriatic nail involvement. Patients undergo radiographic assessment of peripheral and axial joints at 2-year intervals (3) . The reading of these radiographs is performed independently of the clinical and US data by 2 rheumatologist experts in PsA (VC, DG). Axial involvement was defined by the modified New York criteria for ankylosing spondylitis (AS) (23) as the presence of bilateral sacroiliitis grade ≥2 or unilateral sacroiliitis grade ≥3.
Available consecutive PsA patients who fulfilled the Classification of Psoriatic Arthritis Study Group criteria (24) were recruited for a single US assessment. The recruitment took place from June 2011 to October 2012 (this group of patients participated in our previous enthesitis study in PsA) (25) and from January 2014 to December 2015. Patients were recruited randomly and assessed independently from their clinical data. The study was approved by the University Health Network Research Ethics Board. All patients provided written informed consent.
US assessment of enthesitis. All US assessments were performed by a single rheumatologist (LE) who has 7 years of experience in MSUS and assessment of enthesitis. The US device was a MyLab 70 XVG scanner (Esaote) equipped with a 6-18-MHz linear transducer (Esaote). Power Doppler settings were standardized with a Doppler frequency of 8.3-10 MHz (depending on body habitus), pulse repetition frequency of 750 Hz, and a wall filter of 2. Patients' entheseal sites were assessed bilaterally according to the Madrid Sonography Enthesitis Index (MASEI) scoring system including the quadriceps tendons insertions into the patella, patellar tendons insertions into the patella and tibial tuberosity, Achilles tendons and plantar fascia insertions into the calcaneus, and triceps tendon insertions into the olecranon process. Each tendon was scanned in both longitudinal and transverse planes, and the scan images were stored as short video files for later reading. Each examination took~20 minutes. The patients were placed in a supine position to assess the patellar and quadriceps entheses. The knee was placed in 30°flexion to assess grayscale abnormalities and in full extension to assess vascularization. The patients were then placed in a prone position with the feet over the end of the examination table for assessment of the Achilles tendon and plantar fascia entheses. The triceps tendon enthesis was assessed with the elbow flexed to 90°.
The MASEI was used to generate a global score (ranging from 0 to 136) that reflects the severity of entheseal abnormalities in each patient (26) . The enthesopathy US grayscale features of this index include thickening and structural changes of the tendon insertion, calcific deposits at the tendon insertion, and bony changes including erosions and enthesophyte formation as defined by de Miguel et al (26) . The thickness of the enthesis was measured at the insertion of the deeper tendon margin into the bone in a longitudinal axis. Bursitis was defined as a well-circumscribed, localized anechoic or hypoechoic area at the site of an anatomic bursa, which was compressible by the transducer. Vascularization was assessed by power Doppler within 2 mm of the cortical bone insertion. The total MASEI score was further categorized into 1) bone score, including calcific deposits, erosions, and enthesophytes, and 2) soft tissue score, including thickening and structural changes of the tendon insertion, bursitis, and vascularization. Categorization into bone/ chronic damage and inflammatory/soft tissue lesions has been used previously (27) . Reading of the US scans was performed independently from the clinical data by a single reader (LE). The intraobserver intraclass correlation coefficient for the MASEI was 0.8 (25) . HLA genotyping. HLA-B and HLA-C genotyping of DNA extracted from peripheral blood was performed using LabType SSO typing kits according to the instructions of the manufacturer (One Lambda). To minimize false-positive results due to multiple testing, the analysis was limited to the following 6 HLA alleles that were validated as PsA susceptibility alleles (17, 18) : B*27, B*38:01, B*39:01, B*44:02/44:03, B*08:01, and C*06:02.
Statistical analysis. Continuous data were expressed as the mean AE SD, and categorical variables were expressed as frequencies and percentages. The association between the HLA susceptibility allele for PsA (the primary predictor) and the severity of sonographic enthesitis by MASEI score (global score and its subscores as outcomes) was assessed in linear regression models. Multivariate regression analyses were then performed including all HLA alleles that achieved significance at the 5% level and the following potential confounders as model covariates: age, sex, BMI, use of biologic medications (ever versus never), and PsA duration. The interaction between each HLA allele and the model covariates was assessed. A series of sensitivity analyses restricted the regression models to Caucasians to account for potential population stratification bias. The effect of the MASEI score was expressed through its regression coefficients (b) with their respective 95% confidence intervals (95% CIs) and P values. The effect of a covariate was considered statistically significant if the P value was less than 0.05. Statistical computations were performed using SAS software, version 9.4 (SAS Institute).
RESULTS
Baseline characteristics of the patients. Two hundred twenty-five patients were included in the study ( Table 1 ). The mean AE SD age was 56.1 AE 12.7 years, and the mean AE SD PsA duration was 16.9 AE 12.3 years. The majority of patients were men (57.8%), and the majority Caucasian (87.6%). The mean AE SD tender and swollen joint counts were 2.4 AE 5.2 and 1.2 AE 3.3, respectively, and 13.3% had clinical enthesitis. Axial involvement was found in 41.8% of the patients. The mean AE SD MASEI score was 15.7 AE 12.5. At the time of assessment, 45.5% of the patients were receiving conventional disease-modifying antirheumatic drugs (DMARDs), and 53.6% were receiving biologic agents. The frequencies of the HLA alleles were as follows: HLA-B*27 15.6%, HLA-B*38:01 18.2%, HLA-B*39:01 4.9%, HLA-B*44:02/44:03 21.3%, HLA-B*08:01 16.9%, and HLA-C*06:02 27.6% (Table 1) .
Association between HLA alleles and MASEI score. In the univariate analysis, the presence of HLA-B*27 was associated with a higher score of sonographic enthesitis (b = 6.26 [95% CI 1.83, 10.69]), while the presence of HLA-C*06:02 was associated with a lower enthesitis score (b = -4.11 [95% CI -7.73, -0.50]) ( Table 2) . 
DISCUSSION
Exploring the connections between genetics and the subphenotypes of PsA can lead to better understanding of the pathophysiologic basis of this disease. The current study demonstrated that the presence of HLA-B*27 was associated with a higher sonographic enthesitis score. Furthermore, the effect of HLA-B*27 on the severity of enthesitis increased with prolonged PsA. Similar relationships were observed with the sonographic enthesitis bone subscore.
The HLA class I alleles confer the strongest relative genetic risk of PsA, and within this region, HLA-B*27 is the most important genetic risk factor for the SpA disease group (16) (17) (18) ). An animal model study has demonstrated that overexpression of HLA-B*27 leads to peripheral arthritis, spondylitis, colitis, uveitis, skin lesions, and orchitis (28) . Epidemiologic studies showed an increased frequency of HLA-B*27 in the different SpA subgroups, including AS, reactive arthritis, inflammatory bowel disease-related arthritis, and PsA (29) . HLA-B*27 is strongly associated with PsA but not with psoriasis, and therefore it is considered a specific and independent (17, 18) . Despite the strong link between HLA-B*27 and PsA, only 15.6% of the patients in our study carried at least 1 copy of the HLA-B*27 allele. This value corresponds to those in other cohorts of PsA patients (17) . The presence of the HLA-B*27 allele is associated with a worse PsA disease course manifesting with earlier onset of arthritis, axial disease, and progression of joint damage (19, (30) (31) (32) . Consistent with these observations, the current study showed a positive association between HLA-B*27 and more severe sonographic enthesitis in PsA patients. The association between enthesitis and HLA-B*27 among patients with PsA was previously reported by Haroon et al (19) . They found that the presence of HLA-B*27:05:02 was associated with a 3.7-fold greater chance of having clinical enthesitis, and that this association was restricted to those carrying the HLA-B*27:05:02;C*01:02:01 haplotype (odds ratio 4.7). Our study strengthens the findings of Haroon et al by using a more accurate methodology for enthesitis evaluation.
The observed relationship between HLA-B*27 and enthesitis supports the notion that HLA alleles are involved in determining different subphenotypes of PsA, such as enthesitis. The underlying mechanism linking HLA-B*27 and enthesitis is unknown. McGonagle et al found that the presence of HLA-B*27 was associated with more intense bone edema in patients with mechanical and inflammatory plantar fasciitis. They proposed that while the initial trigger of enthesitis may be mechanical microtrauma which can occur in HLA-B*27-negative individuals, in HLA-B*27-positive subjects the inflammatory response is perpetuated and becomes chronic, involving the bone and the adjacent fibrocartilage (33) . Consistent with this hypothesis, a recent crosssectional study demonstrated that enthesitis is a marker for worse outcome in patients with PsA, by showing an association between sonographic enthesitis and the extent of peripheral and axial radiographic damage (34).
Our study did not demonstrate an independent association between the remaining HLA alleles and sonographic enthesitis. The presence of HLA-C*06:02 was associated with a lower enthesitis score in univariate analysis; however, this association was of borderline statistical significance in the multivariate analysis. HLA-C*06:02 is a genetic marker of skin psoriasis and it is associated with earlier onset and more severe skin disease (35) . Ho et al reported that the presence of HLA-C*06 is associated with less severe musculoskeletal manifestations in patients with PsA (36); however, others could not find any relationship between this allele and PsA phenotypes (19) . Other PsA risk alleles that have been shown previously to be related to synovitis-based manifestations of PsA, including HLA-B*08:01, which was linked with joint fusions and deformities (19), were not associated with enthesitis in our study.
Our study had several limitations. First, enthesitis is a dynamic process, and some of the sonographic lesions assessed, especially power Doppler vascularization, can change as a result of treatment. Our study population included predominantly patients with longstanding PsA, the majority of whom were treated with biologic or nonbiologic DMARDs. This may have led to suppression of vascularization at the enthesis; however, the MASEI scores entheseal lesions that represent damage, such as enthesophytes and erosions, which are not expected to change with treatment. Hence, it allowed assessment of the impact of entheseal inflammation throughout the course of the disease even if the patients did not have active enthesitis at the time of assessment. Second, since this was an exploratory study, we did not have a validation cohort. Thus, we restricted the number of tested alleles to a maximum of 6 to reduce the chance of falsepositive results due to testing of multiple alleles. However, due to the restriction of the number of tested HLA alleles, it is possible that other HLA alleles not assessed in this study may have contributed to enthesitis susceptibility. This study also had several strengths, the most notable of which is that it is the largest study to date in which US was used to characterize PsA phenotypes and their association with genetic markers. The clinical assessment of enthesitis can be challenging, and US can improve the precision of detecting this important feature of PsA.
In conclusion, the results of this study suggest that HLA-B*27 is associated with the extent of enthesitis in patients with PsA. The effect of this allele on the extent of sonographic enthesitis increases with longer disease duration, which represents accumulation of bony entheseal damage over time. These findings highlight the potential genetic predisposition to enthesitis and the importance of certain HLA alleles in determining PsA subphenotypes. Further larger studies in different populations are needed to evaluate enthesitis using advanced imaging modalities and to examine additional genetic markers.
